Evidence map›Paper›PMID 35078812›Full record

SynthesisBMJ global health2022

Prevalence of chronic kidney disease in Asia: a systematic review and analysis.

Thaminda Liyanage, Tadashi Toyama, Carinna Hockham, Toshiharu Ninomiya, Vlado Perkovic, Mark Woodward, Masafumi Fukagawa, Kunihiro Matsushita, Kearkiat Praditpornsilpa, Lai Seong Hooi and 5 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMJ global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 184 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
184citing papers in PubMed, 9 pooled it
44.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

184 citing papers in PubMed, 9 syntheses or guidelines pooled it, 321 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

124 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 8 countries.

Thaminda Liyanage *The George Institute for Global Health, Newtown, New South Wales, Australia.
Tadashi Toyama *Department of Nephrology and Laboratory Medicine, Kanazawa University, Kanazawa, Japan.
Carinna HockhamThe George Institute for Global Health, Imperial College London, London, UK.
Toshiharu NinomiyaDepartment of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Kyushu, Japan.
Vlado PerkovicThe George Institute for Global Health, Newtown, New South Wales, Australia.
Mark WoodwardThe George Institute for Global Health, Newtown, New South Wales, Australia.
Masafumi FukagawaDivision of Nephrology, Endocrinology, and Metabolism, Tokai University School of Medicine, Japan, Japan.
Kunihiro MatsushitaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Kearkiat PraditpornsilpaDivision of Nephrology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Lai Seong HooiHospital Sultanah Aminah, Johor Bahru, Malaysia.
Kunitoshi IsekiOkinawa Heart and Renal Association (OHRA) and Clinical Research Support Center, Tomishiro Central Hospital, Okinawa, Japan.
Ming-Yen LinDivision of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.ORCID 0000-0002-8194-4833
Heide A Stirnadel-FarrantGlaxoSmithKline, Value Evidence Outcomes - Epidemiology, Stevenage, Hertfordshire, UK.
Vivekanand JhaThe George Institute for Global Health, India, New Dehli, India.
Min JunThe George Institute for Global Health, Newtown, New South Wales, Australia mjun@georgeinstitute.org.au.
Johns Hopkins University · USUNSW Sydney · AUChulalongkorn University · THGlaxoSmithKline (United Kingdom) · GBKanazawa University · JPKaohsiung Medical University · TWKyushu University · JPManipal Academy of Higher Education · INSultanah Aminah Hospital · MYThe George Institute for Global Health · GBThe University of Sydney · AUTokai University · JPTomishiro Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe burden of chronic kidney disease (CKD) is growing rapidly around the world. However, there is limited information on the overall regional prevalence of CKD, as well as the variations in national prevalence within Asia. We aimed to consolidate available data and quantify estimates of the CKD burden in this region.

methodsWe systematically searched MEDLINE, Embase and Google Scholar for observational studies and contacted national experts to estimate CKD prevalence in countries of Asia (Eastern, Southern and South Eastern Asia). CKD was defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m

resultsThere was substantial variation in overall and advanced (eGFR <30 mL/min/1.73 m

conclusionThe large number of people with CKD, and the substantial number with advanced CKD, show the need for urgent collaborative action in Asia to prevent and manage CKD and its complications.

Indexed as

Renal Insufficiency, ChronicAdultAsiaAsia, SoutheasternHumansPrevalenceRisk Factorsepidemiologypublic healthsystematic review

Identifiers

PMID35078812
PMCPMC8796212
OpenAlexW4206996545

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.